Recent developments include significant legal actions to enforce LNP technology patents, receipt of a major settlement payment from Moderna, FDA Fast Track designation for imdusiran, and clinical trial progress for cHBV treatments.

• In July 2026, Arbutus and Genevant filed three international lawsuits against Pfizer/BioNTech to enforce patents protecting their LNP technology [N2].
• On July 8, 2026, Arbutus received $178.4 million as its share of a $950 million noncontingent settlement payment from Moderna, related to patent litigation [S2].
• The FDA granted Fast Track designation to imdusiran for the treatment of chronic hepatitis B in April 2026 [S2].
• In May 2026, Arbutus aligned with the FDA on the design and safety parameters for a proposed Phase 2b clinical trial of imdusiran [S2].
• Q2 2025 revenue surged 529%, and the company beat earnings and revenue estimates in that quarter [N7][N8].
• Arbutus reacquired rights to imdusiran in Greater China in June 2025, concluding its partnership with Qilu Pharmaceutical [N11].
• The company is evaluating a return of capital to shareholders in 2026 following receipt of settlement proceeds [S2].
• Arbutus shares fell 19% in January 2026 due to European patent revocation [N12].
• Notable option activity and stock gains related to patent dispute settlements were reported in March 2026 [N4][N5].
• Chardan Capital maintained a buy recommendation on Arbutus in November 2025 [N6].

Arbutus Biopharma's proprietary LNP technology is a foundational platform for mRNA therapeutics, with ongoing patent enforcement potentially securing significant licensing revenues. Clinical data from imdusiran trials show meaningful reductions in HBV markers and functional cure in some patients, supporting its potential as a cornerstone therapy for cHBV. The FDA's Fast Track designation and alignment on Phase 2b trial design indicate regulatory engagement. The recent $950 million settlement payment from Moderna and potential for additional contingent payments provide substantial capital resources. The company's strong liquidity and absence of debt support continued development and strategic flexibility. Equity ownership in Genevant offers additional value through dividends and technology collaboration.

Arbutus faces risks from ongoing patent litigation, which could result in unfavorable rulings affecting its intellectual property rights and royalty streams. Clinical development of imdusiran and AB-101 remains subject to typical biopharmaceutical risks including trial outcomes, regulatory approvals, and market acceptance. The company reported net losses and modest revenue, indicating ongoing cash burn and reliance on external funding or milestone payments. The conclusion of partnerships, such as with Qilu Pharmaceutical, and restructuring efforts reflect operational challenges. Patent revocations, such as the European patent revocation, have impacted share price and highlight legal uncertainties. The company's ability to sustain development and commercialization efforts depends on successful execution and favorable legal outcomes.

Arbutus Biopharma's moat is anchored in its proprietary lipid nanoparticle (LNP) technology, which is a critical enabling platform for mRNA delivery in therapeutics and vaccines. This technology underpins the company's intellectual property portfolio, which is actively defended through litigation against major industry players such as Pfizer/BioNTech and Moderna. The company's RNAi therapeutic imdusiran and oral PD-L1 inhibitor AB-101 target chronic hepatitis B, a disease with significant unmet medical need, supported by clinical data demonstrating functional cure potential. The combination of proprietary technology, clinical-stage assets, and ongoing royalty streams from licensed LNP technology contributes to a differentiated position in the biopharmaceutical landscape. However, the moat is subject to risks from patent litigation outcomes and the need for successful clinical development and regulatory approvals.

• Patent Litigation Risk: Ongoing lawsuits against Pfizer/BioNTech and Moderna regarding LNP technology patents present legal and financial uncertainties that could impact royalty revenues and intellectual property rights.
• Clinical Development Risk: The success of imdusiran and AB-101 depends on clinical trial outcomes, regulatory approvals, and market acceptance, with inherent risks of delays or failures.
• Financial Risk: The company has reported net losses and relies on settlement payments, collaborations, and potential equity financing to fund operations, which may affect financial stability.
• Operational Risk: Restructuring, cessation of discovery efforts, and partnership changes may impact the company's ability to advance its pipeline and maintain organizational effectiveness.

• Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious disease, specifically chronic hepatitis B (cHBV).
• The company is developing imdusiran (AB-729), a proprietary GalNAc-conjugated, subcutaneously-delivered RNA interference (RNAi) therapeutic, and AB-101, an oral PD-L1 inhibitor, both targeting cHBV treatment.
• Imdusiran aims to suppress all HBV antigens including HBsAg, which is key to enabling immune response potentiation; over 200 patients have been dosed in Phase 1 and Phase 2a trials.
• Clinical data show imdusiran provides meaningful reductions in HBsAg, HBV DNA, and HBV RNA, with some patients achieving functional cure and remaining off nucleos(t)ide analogue (NA) therapy for extended periods.
• AB-101 has completed Phase 1a/1b trials showing safety, tolerability, and evidence of receptor occupancy and HBsAg decline in some cHBV patients.
• The company has completed two Phase 2a clinical trials combining imdusiran with other agents, showing functional cure rates and durable viral suppression off NA therapy.
• Arbutus holds and defends intellectual property related to lipid nanoparticle (LNP) technology used in mRNA delivery, which is the subject of ongoing patent infringement lawsuits against Pfizer/BioNTech and Moderna.
• In March 2026, Arbutus and related party Genevant settled patent litigation with Moderna, receiving a $950 million noncontingent lump sum payment, with potential for an additional $1.3 billion contingent payment.
• Arbutus owns approximately 16% of Genevant's outstanding common equity and anticipates a material dividend from Genevant in 2026.
• The FDA granted Fast Track designation to imdusiran for cHBV treatment in April 2026, and the company has aligned with the FDA on Phase 2b clinical trial design.
• Financial snapshot as of June 30, 2026, includes $19.2 million in cash and equivalents, $273.9 million in current assets, $3.4 million in current liabilities, yielding a current ratio of 81.42 and a cash ratio of 27.54.
• Q2 2026 revenue was $1.014 million with a net loss of $5.143 million for the quarter.
• Operating expenses in 2025 decreased compared to 2024 due to ceasing discovery efforts, workforce reductions, and focusing on clinical development of imdusiran and AB-101.
• The company has no outstanding debt as of December 31, 2025, and has financed operations through equity sales, collaborations, royalties, and government grants.
• Arbutus reacquired global rights to imdusiran in Greater China in June 2025 after concluding a partnership with Qilu Pharmaceutical.
• The company is evaluating a return of capital to shareholders in 2026 following receipt of settlement proceeds.
• Arbutus continues to protect and enforce its intellectual property through ongoing litigation internationally.
• Recent news includes filing international lawsuits against Pfizer/BioNTech in July 2026, and receiving the Moderna settlement payment in July 2026.
• The company reported Q2 2025 revenue surge of 529% and beat earnings and revenue estimates in that period.
• Chardan Capital maintained a buy recommendation on Arbutus in November 2025.
• Arbutus shares fell 19% in January 2026 due to European patent revocation.
• Notable option activity and stock gains related to patent dispute settlements were reported in March 2026.